Evidence map›Paper›PMID 42116166›Full record

ArticleJournal of experimental & clinical cancer research : CR2026

Nanovaccines with ferroptosis, necroptosis and STING-activation for synergistic immunotherapy.

Jia-Rui Du, Mu-Le Tu, Yong-Xu Xia, Yuan-Qiang Lin, Rui Yang, Chang Weng, Yi Liu, Hao Zhang, Hui Wang, Wen-Jie Feng and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jia-Rui DuDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, 130033, P.R. China.
Mu-Le TuDepartment of Ultrasound, The Third Affiliated Clinical Hospital of Changchun University of Chinese Medicine, Changchun, 130117, P. R. China.
Yong-Xu XiaDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, 130033, P.R. China.
Yuan-Qiang LinDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, 130033, P.R. China.
Rui YangState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, P. R. China.
Chang WengState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, P. R. China.
Yi LiuInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, P. R. China.
Hao ZhangInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, P. R. China.
Hui WangDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, 130033, P.R. China.
Wen-Jie Feng *Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, P. R. China. wenjiefeng@jlu.edu.cn.
Deng-Ke Teng *Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, 130033, P.R. China. tengdk@jlu.edu.cn.ORCID http://orcid.org/0000-0003-4266-8941

Funding

Department of Science and Technology of Jilin Province YDZJ202201ZYTS594
6 · The paper itself

Abstract

Nanovaccines based on immunogenic cell death (ICD) present a promising strategy in tumor immunotherapy, serving as a bridge connecting tumor cell death to the induction of anti-tumor immunity. However, their efficacy is severely limited by the immunologically silent nature of apoptosis-dependent ICD and the immunosuppressive tumor microenvironment (TME). In this work, we designed a metal‒polyphenol network nanovaccine (SRF@FeShik-cGAMP/HA). Upon reaching the tumor tissue through specific targeting, the nanovaccines disassemble within the tumor cells, releasing the Fenton reaction catalyst ferrous iron (Fe

Indexed as

FerroptosisImmunotherapyMembrane ProteinsNanovaccinesNecroptosisAnimalsCell Line, TumorcGAS-STING Signaling PathwayHumansMiceNaphthoquinonesSorafenibSTING ProteinTumor MicroenvironmentMembrane ProteinsNanovaccinesNaphthoquinonesshikoninSorafenibSTING ProteinFerroptosisImmunogenic cell deathImmunotherapyNanovaccinesNecroptosisSTING pathway

Identifiers

PMID42116166
PMCPMC13255514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.